Transaction overview
Metagenics, a leading US-based nutritional supplement company backed by Gryphon Investors, acquired Symprove, the UK’s number one probiotic brand. The deal closed on January 1, 2026, although financial details were not disclosed. Symprove is renowned for its clinically proven water-based formulation that addresses digestive issues and improves gut microbiome health.
Deal structure and financing
The exact equity and debt split of the transaction are undisclosed, as well as any specific lead banks involved in financing the deal. Given Metagenics' backing by Gryphon Investors, it is likely the acquisition was partially funded through private equity capital. The terms did not include any seller-retained stake or lock-up provisions for Symprove's founders. There were no public indications of IPO optionality following this transaction.
Strategic context
Metagenics acquired Symprove to expand its global network of healthcare practitioner partnerships and improve patient outcomes with Symprove’s patented delivery technology. This acquisition aligns with Metagenics' commitment to delivering science-backed supplements that support health goals. For Symprove, the deal represents a significant strategic move to leverage Metagenics’ extensive distribution channels and research capabilities in the US market.
Historical context reveals that Spayne Lindsay & Co., which advised on this transaction for Metagenics, previously helped sell Symprove to bd-capital in 2020. This continuity of advisory support underscores the importance of industry expertise and long-term relationships in driving successful M&A outcomes within the health and wellness sector.
Regulatory path
The acquisition did not require specific regulatory approvals or remedies as it was below the thresholds triggering mandatory filings for HSR Act review by the US Federal Trade Commission (FTC) or any corresponding EU competition authority filings. Given Symprove’s primary market presence in the UK, the Competition and Markets Authority (CMA) would have been the relevant regulator had a filing been required. However, no such filings were made based on the deal value not reaching regulatory thresholds for review.
The transaction is considered to fall within the private M&A landscape without significant antitrust scrutiny due to the non-disclosed financial terms and the companies’ market positions.